Outsourcing in Clinical Trials Southern California 201423-24 September 2014, La Jolla, CA
Following multiple requests from our regular attendees at our other Outsourcing Clinical Trials events, we were very pleased to bring the OCT series to Southern California for the first time in 2013. The event was a huge success, with over 200 pharmaceutical, biotechnology and medical device professionals attending, and we’re now building a bigger and better event for 2014.
Leaders within the industry attend our OCT events to learn from case-study based presentations, network with their peers, discover new solutions and services and find answers to all of their clinical challenges. This event is unique as it caters individually to 3 company types (biotech/pharma, virtual, medical device) with specific content on all aspects of clinical outsourcing: from informed sourcing and efficient contract negotiation through to effective management, monitoring and communication techniques. The agenda boasts presentations, case studies, panel discussions and roundtables all presented and facilitated by a high calibre speaking faculty local to this industry hub.
Whether you are a senior professional in a global pharmaceutical company or a smaller company looking to expand, access to insight and knowledge about the latest pharmaceutical trends is vital.
The Outsourcing Clinical Trial series is growing every year. View the full list of upcoming events to make sure you don’t miss any news. The list of websites will be updated as soon as new events are live so check back regularly
Primary delegates for this event are those with responsibility for clinical outsourcing decisions and strategy within biotechnology, pharmaceutical, virtual and medical device companies throughout Southern California.
Outsourcing in Clinical Trials Southern California boasts a fantastic exhibition of clinical service providers and industry specialists. Our exhibition area is already filling up due to the fantastic launch event which took place this year. If you have a service or solution you would like to promote at this event, please use the details below to make contact with our commercial team.
AstraZeneca and Amgen have reported positive results from the multi-arm Phase III AMAGINE-2 trial of brodalumab in patients with moderate-to-severe plaque psoriasis.
Bristol-Myers Squibb (BMS) and Five Prime Therapeutics have entered into an exclusive clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of the combination of Opdivo (nivolumab) and FPA008 in six tumour typ…
Danish biotechnology firm Genmab’s collaboration partner, Janssen Biotech (Janssen) is planning to initiate a Phase II trial of daratumumab to treat patients with smoldering multiple myeloma.
US-based Intra-Cellular Therapies has reported additional results from a Phase I/II clinical trial (ITI-007-200) of ITI-007, in healthy geriatric subjects (trial Part 1) and in patients with dementia, including Alzheimer's disease (AD) (trial Part 2)…
US-based biopharmaceutical firm Xenetic Biosciences' licence partner Pharmsynthez has completed dosing in its Phase II clinical trial with MyeloXen in patients with relapsing remitting and secondary progressive (RRSP) multiple sclerosis (MS).
Neurotrope has completed dosing in its Phase IIa clinical trial of Bryostatin-1, a potent modulator of the enzyme protein kinase C epsilon (PKCe), to treat patients with Alzheimer's disease (AD).